Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 11, 2021 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Presents New Data on obe-cel in r/r Indolent B Cell Lymphomas and gives an update of obe-cel in r/r Adult ALL at the European Hematology Association Virtual Congress

Obe-cel achieves 100% complete remission rate in a cohort of indolent B Cell Non-Hodgkin lymphoma patients with excellent CAR T engraftment, expansion, and persistence No ICANS or high grade...